Cancer Research

Scientists developed a monoclonal antibody (mAb) that selectively targets pancreatic cancer cells. This is an early step toward new treatments for a deadly malignancy that is the third leading cause of cancer deaths.

BBO-11818 is now in clinical trials may one day be a targeted treatment for KRAS-driven cancers.

Study results of BBO-8520 and BBO-11818 will be presented in Chicago.

A four-year effort revealed new information about a less-studied KRAS variant.

Many cancer cells–and lung cancers in particular–have an abnormal number of chromosomes, a feature that can help shield them from therapeutic attack. But now scientists are exploring ways to turn the tables and use this abnormality as a weapon against cancer. In a recent example of this, scientists at the Frederick National Laboratory for Cancer…

A team from the National Cancer Institute RAS Initiative and collaborators at Lawrence Livermore National Laboratory and BridgeBio TheRas Pharma have made a dual discovery involving the much-studied protein KRAS, identifying a better model and a highly potent anticancer compound. Their findings, the product of a long-term partnership, appear…

The cancer community will come together for a two-day conference designed to celebrate Black contributions in cancer research and to connect future investigators and collaborators, in order to pave the way for the next generation of Black cancer research professionals.  Black in Cancer, a US/UK-based organization and the Frederick National…

We built and deployed this repository to help the medical community maximize canine data’s contributions to oncology.

Morehouse joins the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC).

Deep learning demonstrated a method of predicting genetic subtypes and mutations from histology